Found: 14
Select item for more details and to access through your institution.
Phase 1 study of safety, pharmacokinetics, and antiviral activity of SARS-CoV-2 neutralizing monoclonal antibody ABBV-47D11 in patients with COVID-19.
- Published in:
- Pharmacology Research & Perspectives, 2023, v. 11, n. 1, p. 1, doi. 10.1002/prp2.1036
- By:
- Publication type:
- Article
Response to Emergence of Middle East Respiratory Syndrome Coronavirus, Abu Dhabi, United Arab Emirates, 2013-2014.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Transmission of Middle East Respiratory Syndrome Coronavirus Infections in Healthcare Settings, Abu Dhabi.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Ibrutinib for Hospitalized Adults With Severe Coronavirus Disease 2019 Infection: Results of the Randomized, Double-Blind, Placebo-Controlled iNSPIRE Study.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 5, p. 1, doi. 10.1093/ofid/ofac104
- By:
- Publication type:
- Article
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Patients With Chronic Hepatitis C Virus Genotype 1 Infection Receiving Opioid Substitution Therapy: A Post Hoc Analysis of 12 Clinical Trials.
- Published in:
- Open Forum Infectious Diseases, 2018, v. 5, n. 11, p. N.PAG, doi. 10.1093/ofid/ofy248
- By:
- Publication type:
- Article
Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co‐formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults.
- Published in:
- Clinical Pharmacology in Drug Development, 2023, v. 12, n. 10, p. 945, doi. 10.1002/cpdd.1325
- By:
- Publication type:
- Article
Longitudinal Molecular and Serological Evidence of SARS-CoV-2 Infections and Vaccination Status: Community-Based Surveillance Study (CONTACT).
- Published in:
- Infectious Diseases & Therapy, 2024, v. 13, n. 4, p. 633, doi. 10.1007/s40121-024-00923-4
- By:
- Publication type:
- Article
Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE‐I Part II).
- Published in:
- Health Science Reports, 2019, v. 2, n. 3, p. N.PAG, doi. 10.1002/hsr2.92
- By:
- Publication type:
- Article
Trends in Tuberculosis -- United States, 2013.
- Published in:
- MMWR: Morbidity & Mortality Weekly Report, 2014, v. 63, n. 11, p. 229
- By:
- Publication type:
- Article
Evaluation of community-based treatment for drug-resistant tuberculosis in Bangladesh.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Change in the hepatic profile of hepatitis C virus genotype 4–infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE‐II study.
- Published in:
- Journal of Medical Virology, 2018, v. 90, n. 11, p. 1739, doi. 10.1002/jmv.25243
- By:
- Publication type:
- Article
Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials.
- Published in:
- Gut & Liver, 2021, v. 15, n. 6, p. 895, doi. 10.5009/gnl20321
- By:
- Publication type:
- Article
High Efficacy of Glecaprevir/Pibrentasvir in Patients Infected with Chronic Hepatitis C Virus Genotype 1 or 2 from South Korea.
- Published in:
- Gut & Liver, 2019, v. 13, n. 6(suppl. 1), p. 89
- By:
- Publication type:
- Article
A Phase-I pharmacokinetic, safety and food-effect study on flubentylosin, a novel analog of Tylosin-A having potent anti-Wolbachia and antifilarial activity.
- Published in:
- PLoS Neglected Tropical Diseases, 2023, v. 17, n. 7, p. 1, doi. 10.1371/journal.pntd.0011392
- By:
- Publication type:
- Article